Wave Life Sciences Slips as Obesity Data Fails to Convince

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company's obesity candidate.
Open original source